Accepted for/Published in: JMIR Dermatology
Date Submitted: Aug 26, 2021
Date Accepted: Jul 17, 2022
Date Submitted to PubMed: Aug 26, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
From the Cochrane Library: Dietary supplements for established atopic eczema
ABSTRACT
Atopic eczema is a chronic inflammatory skin condition, affecting 5% to 20% of people worldwide, with no current cure. While there are many available treatment options that help improve atopic eczema, patients in whom these treatments did not work or who fear their long-term effects may look to diet for solutions. Nutritional supplements are a vast and growing industry, and patients often turn to oral supplements as complementary or alternative treatment options for a variety of health conditions. Nutritional supplements are not required to prove efficacy or safety before becoming available to consumers, as they are regulated by the FDA as foods instead of drugs. Given their growing popularity and industry characteristics, it is important for physicians to be knowledgeable about these ingredients in order to counsel patients. A 2012 Cochrane review, “Dietary supplements for established atopic eczema” offers a comprehensive review of evidence regarding popular dietary supplements used in atopic eczema.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.